TransThera Sciences (Nanjing), Inc. (02617.HK) Fiyatı

TransThera Sciences (Nanjing), Inc. engages in the research and development of clinical biopharmaceutics. The company is headquartered in Nanjing, Jiangsu and currently employs 121 full-time employees. The company went IPO on 2025-06-23. The firm's core product Tinengotinib is a registrational clinical stage, internally discovered and developed, MTK inhibitor indicated for certain relapsed or refractory, drug-resistant solid tumors. The firm's oncology pipeline includes TT-00973 (against AXL), TT-01488 (for hematologic malignancies), TT-01688 (for inflammatory diseases) and TT-00920 (for chronic heart failure). The products are capable of being efficacious in a broad range of cancer types (including prostate cancer, HCC, breast cancer, and BTC). The company is also applied to cure hepatocellular carcinoma, breast cancer, biliary tract cancer and Pan-FGFR solid tumor.